NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/04/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,296.17 mln
Float61.74 mln
Earnings Date11/17/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
28.54
Transformational upside
Relative Strength
20
/ 100
Significantly lagging
Debt / Equity
0.24
Very low leverage
ROE
-80.91
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
MoonLake Immunotherapeutics is a Swiss biotech company working to bring new treatments to patients suffering from inflammatory skin and joint conditions. Its primary focus is Sonelokimab, a next-generation molecule designed to block key proteins that drive inflammation, targeting conditions such as psoriasis, psoriatic arthritis, and related disorders. Founded in 2021 and based in Zug, Switzerland, the company is currently running clinical trials to advance this therapy toward approval.
